Circulating T Cell Subsets in Type 1 Diabetes

Circulating T Cell Subsets in Type 1 Diabetes

Type 1 diabetes (T1D) is a complex disease driven by the immune system attacking the insulin-producing beta cells in the pancreas. Understanding the role of different T cell subpopulations in the development and progression of T1D is crucial. By employing flow cytometry to compare the characteristic...

Full description

Saved in:

Bibliographic Details
Main Authors:	Aldo Ferreira-Hermosillo, Paola Santana-Sánchez, Ricardo Vaquero-García, Manuel R. García-Sáenz, Angélica Castro-Ríos, Adriana K. Chávez-Rueda, Rita A. Gómez-Díaz, Luis Chávez-Sánchez, María V. Legorreta-Haquet
Format:	Article
Language:	English
Published:	MDPI AG 2025-01-01
Series:	Cells
Subjects:	type 1 diabetes PD1 PRL T cells
Online Access:	https://www.mdpi.com/2073-4409/14/1/48
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Plasma prolactin axis shift from placental to pituitary origin in late prepartum mice
by: Taku James Sairenji, et al.
Published: (2024-07-01)

Increased serum soluble PD-l1 levels in patients with advanced stages of chronic kidney disease
by: Ayaka Hayashi, et al.
Published: (2025-01-01)

Developing a risk score using liquid biopsy biomarkers for selecting Immunotherapy responders and stratifying disease progression risk in metastatic melanoma patients
by: Amalia Azzariti, et al.
Published: (2025-02-01)

Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies
by: Yizhou Zhang, et al.
Published: (2024-12-01)

Toxic epidermal necrolysis induced by nivolumab therapy for unresectable intraperitoneal cancer
by: Hiroyoshi Nozaki, et al.
Published: (2025-01-01)

Discovery of novel biphenyl compounds bearing hydroxamic acid moiety as the first PD-L1/class I HDACs dual inhibitors
by: Dandan Yuan, et al.
Published: (2025-12-01)

Sigma1 inhibitor suppression of adaptive immune resistance mechanisms mediated by cancer cell derived extracellular vesicles
by: Paola A. Castagnino, et al.
Published: (2025-12-01)

Extraction, GC-MS analysis, cytotoxic, anti-inflammatory and anticancer potential of Cannabis sativa female flower; in vitro, in vivo and in silico
by: Waqas Safir, et al.
Published: (2025-02-01)

Inosine enhances the efficacy of immune‐checkpoint inhibitors in advanced solid tumors: A randomized, controlled, Phase 2 study
by: Haiqing Zhao, et al.
Published: (2024-09-01)

The Potential Role of sPD-L1 as a Predictive Biomarker in EGFR-Positive Non-Small-Cell Lung Cancer
by: Vesna Ćeriman Krstić, et al.
Published: (2025-01-01)

Infiltration of CD8+ cytotoxic T-cells and expression of PD-1 and PD-L1 in ovarian clear cell carcinoma
by: Mengdi Fu, et al.
Published: (2025-02-01)

Polskie kino. Obywatel a służba bezpieczeństwa
by: Krystyna Duniec, et al.
Published: (2012-06-01)

Changes in PD-1 expression on T lymphocyte subsets and related immune indicators before and after definitive chemoradiotherapy for esophageal squamous cell carcinoma
by: Xueling Shi, et al.
Published: (2025-12-01)

Lutetium-177 labeled iPD-L1 as a novel immunomodulator for cancer-targeted radiotherapy
by: Myrna Luna-Gutiérrez, et al.
Published: (2025-01-01)

EXPRESSION AND CLINICAL CORRELATION OF PD-1/PD-L1 AND VE1(BRAFP.V600E) IN PEDIATRIC LANGERHANS CELL HISTIOCYTOSIS
by: sneha tandon, et al.
Published: (2023-04-01)

Periodontitis promotes tumor growth and immune evasion via PD-1/PD-L1
by: Suli Wang, et al.
Published: (2024-11-01)

Efficacy and safety of immune checkpoint inhibitors in patients with advanced intrahepatic cholangiocarcinoma
by: Ziting Peng, et al.
Published: (2025-02-01)

Efficacy and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a meta-analysis with trial sequential analysis of randomized controlled trials
by: Ji Ren, et al.
Published: (2025-01-01)

PD-1/PD-L1 inhibitors related adverse events: A bibliometric analysis from 2014 to 2024
by: Qingya Song, et al.
Published: (2025-12-01)

Formin protein DAAM1 positively regulates PD-L1 expression via mediating the JAK1/STAT1 axis in pancreatic cancer
by: Rui Xu, et al.
Published: (2025-01-01)

Caerin 1.1/1.9-mediated antitumor immunity depends on IFNAR-Stat1 signalling of tumour infiltrating macrophage by autocrine IFNα and is enhanced by CD47 blockade
by: Junjie Li, et al.
Published: (2025-01-01)

Comparison of the Efficacy and Safety of PD‐1/PD‐L1 Inhibitors in the Treatment of Small Cell Lung Cancer
by: Qichen Zhang, et al.
Published: (2025-01-01)

Progression patterns in patients with advanced hepatocellular carcinoma treated with local therapy, targeted drugs, and PD-1/PD-L1 inhibitors
by: Yanan Zhao, et al.
Published: (2024-08-01)

PD-1/PD-L1在膀胱癌患者外周血T细胞和肿瘤细胞表达
by: 龙兆麟, et al.
Published: (2017-01-01)

ArfGAP with the SH3 Domain, Ankyrin Repeat and PH Domain 1 Inversely Regulates Programmed Death-Ligand 1 Through Negative Feedback of Phosphorylated Epithelial Growth Factor Receptor and Activation of Nuclear Factor-Kappa B in Non-Small Cell Lung Cancer
by: Chiba N, et al.
Published: (2025-01-01)

Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer
by: Cecilia Olsson Ladjevardi, et al.
Published: (2024-11-01)

Germline Human Leukocyte Antigen Status is Associated With Immunotherapy-Induced Pneumonitis and Treatment Response in Patients With Non–Small Cell Lung Cancer With High Programmed Death-Ligand 1 Expression
by: Alvin H.K. Cheung, MBBS, PhD, et al.
Published: (2025-01-01)

Changes in TgAb and TPOAb titers are greater in thyrotoxicosis than isolated hypothyroidism induced by PD-1 blockade
by: Ayana Yamagami, et al.
Published: (2024-05-01)

Differentiation status determines the effects of IFNγ on the expression of PD-L1 and immunomodulatory genes in melanoma
by: Teitur Sævarsson, et al.
Published: (2024-12-01)

Analysis of GH1, GHR and PRL gene polymorphisms for estimation of the genetic diversity of Buryat and Altai cattle breeds
by: I. V. Lazebnaya, et al.
Published: (2018-09-01)

A remarkable and durable response to tislelizumab treatment of an anaplastic thyroid carcinoma without targetable genomic alterations: a case report
by: Jingjing Chai, et al.
Published: (2025-02-01)

Emerging roles of checkpoint molecules on B cells
by: Hiromitsu Asashima, et al.
Published: (2025-01-01)

Przemysł zabawkarski w okresie PRL: potrzeby badawcze, baza źródłowa
by: Małgorzata Przeniosło, et al.
Published: (2024-12-01)

A network comparison on efficacy and safety profiling of PD-1/PD-L1 inhibitors in first-line treatment of advanced non-small cell lung cancer
by: Jie Fu, et al.
Published: (2025-01-01)

Effectiveness and safety of pembrolizumab, nivolumab, and atezolizumab as adjuvant therapy for high-risk muscle-invasive urothelial carcinoma: an indirect comparison
by: Wei Chen, et al.
Published: (2025-01-01)

Escherichia coli combination with PD-1 blockade synergistically enhances immunotherapy in glioblastoma multiforme by regulating the immune cells
by: Guochen Li, et al.
Published: (2025-02-01)

ErbB- and MUC1-targeted CAR-T cell immunotherapy of oral squamous cell carcinoma
by: Saffron E. Summers, et al.
Published: (2023-03-01)

Differences in the intrahepatic expression of immune checkpoint molecules on T cells and natural killer cells in chronic HBV patients
by: Lucile Dumolard, et al.
Published: (2025-01-01)

Immune-related adverse events with PD-1/PD-L1 inhibitors: insights from a real-world cohort of 2523 patients
by: Ting Yan, et al.
Published: (2025-01-01)

Updated Bayesian network meta-analysis on the efficacy and safety of PD−1 versus PD−L1 inhibitors in first−line treatment with chemotherapy for extensive−stage small-cell lung cancer
by: Ke Wang, et al.
Published: (2025-01-01)